https://medibiofarma.com/medibiofarma-announced-the-nomination-of-a-second-development-candidate/ 2019-02-13T09:30:46+00:00 https://medibiofarma.com/medibiofarma-announces-the-completion-of-a-new-financing-round/ 2019-04-02T14:48:15+00:00 https://medibiofarma.com/wp-content/uploads/2019/04/IMG_0802.jpg https://medibiofarma.com/medibiofarma-participated-in-the-startup-spotlight-event-of-the-annual-bio-europe-spring-conference-held-on-march-26-2019-in-vienna-austria/ 2019-04-12T15:07:15+00:00 https://medibiofarma.com/wp-content/uploads/2019/04/Medibiopharma.jpg https://medibiofarma.com/medibiofarma-news-3/ 2019-09-02T07:23:48+00:00 https://medibiofarma.com/wp-content/uploads/2018/05/2.jpg https://medibiofarma.com/medibiofarma-announces-first-subject-dosed-in-mbf-118-clinical-study-new-pparg-covalent-partial-agonist-in-healthy-volunteers/ 2020-07-16T09:47:02+00:00 https://medibiofarma.com/medibiofarma-announces-first-subject-dosed-in-phase-ib-multiple-ascending-dose-study-of-mbf-118-a-new-pparg-covalent-partial-agonist-in-healthy-volunteers/ 2021-07-29T09:39:06+00:00 https://medibiofarma.com/medibiofarma-announces-first-subject-dosed-in-mbf-015-phase-i-clinical-study-new-hdac1-2-inhibitor-in-healthy-volunteers/ 2021-07-29T09:40:59+00:00 https://medibiofarma.com/medibiofarma-announces-the-closing-of-a-new-financing-round-of-above-two-million-euros/ 2022-03-15T09:05:32+00:00 https://medibiofarma.com/medibiofarma-announces-the-first-subject-dosed-in-the-phase-ib-clinical-trial-of-mbf-362-in-cancer-patients-with-solid-tumours/ 2023-03-27T18:45:41+00:00 https://medibiofarma.com/medibiofarma-receives-funding-from-the-crohns-colitis-foundation-to-support-development-of-a-new-antifibrotic-therapy-for-inflammatory-bowel-disease/ 2023-04-12T07:05:41+00:00 https://medibiofarma.com/medibiofarma-announced-the-first-patient-dosed-in-the-phase-iia-clinical-trial-of-mbf-118-in-patients-with-crohns-disease/ 2023-05-16T07:39:08+00:00 https://medibiofarma.com/first-patient-dosed-in-the-phase-iia-clinical-trial-of-mbf-015-in-patients-with-huntingtons-disease/ 2024-03-11T16:27:30+00:00 https://medibiofarma.com/medibiofarma-s-l-announced-the-award-of-the-european-commissionseal-of-excellence-for-their-clinical-asset-mbf-015/ 2025-03-11T11:49:57+00:00 https://medibiofarma.com/wp-content/uploads/2025/03/2025-03-11-12_45_10-Notas-de-Prensa-gayoso0597@gmail.com-Gmail-y-6-paginas-mas-Trabajo_-Micros.png https://medibiofarma.com/palobiofarma-and-medibiofarma-open-new-headquarters-in-the-ainbuilding-in-cordovilla-spain/ 2025-03-11T11:59:32+00:00 https://medibiofarma.com/wp-content/uploads/2025/03/Foto_equipo_Medi_Palobiofarma-scaled.jpg https://medibiofarma.com/medibiofarma-receives-2nd-funding-award-from-the-crohns-colitis-foundation-to-support-development-of-a-new-antifibrotic-therapy/ 2025-09-09T15:07:58+00:00 https://medibiofarma.com/asabys-backed-oriva-therapeutics-launches-to-advance-novel-treatments-for-womens-health/ 2026-01-23T09:32:32+00:00 https://medibiofarma.com/medibiofarma-successfully-completes-phase-2a-clinical-trial-of-mbf-118-for-fibrotic-crohns-disease/ 2026-03-09T16:27:08+00:00